Trial Profile
A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2015
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Neurological disorders; Stroke complications
- Focus Adverse reactions
- Sponsors Acorda Therapeutics
- 02 Dec 2013 New trial record
- 14 Oct 2013 Results were presented at the Annual Meeting of the American Neurological Association in October 2013.